DJIA 17,982.85 270.19 1.53%
NASDAQ 4,941.25 50.04 1.02%
S&P 500 2,085.64 24.62 1.19%
market minute promo


company name or ticker

Obesity Drugs: Orexigen Gains Market Share at Expense of Arena, Vivus

Orexigen's Contrave Sales Recover - Investors Should Look To Europe

Arena's Belviq Scripts Spike - Maintaining This Trajectory Important

Vivus' Qsymia Experiencing Both Prescription Growth And Market Share Erosion

Orexigen's Contrave Resumes Solid Growth Rate

Don't Worry About Orexigen's Obesity Drug EU Approval

Despite what looks initially like bad news for the oral obesity drug, a positive European Commission decision is still likely.

Forget About Ebola Stocks and Invest in This Instead

Instead of Ebola drugmakers, investors may be better served focusing on these healthcare trends.

5-year lows: Vivus, Synta Pharmaceuticals Inc, MVC Capital Inc, and Kemet Corp.

Vivus: Qsymia Sales Dip - Is A Lower Price Needed?

Vivus' Qsymia Headed In The Wrong Direction

See More Articles...